Clinical Trial Detail

NCT ID NCT04172675
Title A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Janssen Research & Development, LLC
Indications

non-invasive bladder urothelial carcinoma

Therapies

Erdafitinib

Gemcitabine

Mitomycin C

Age Groups: adult senior

Additional content available in CKB BOOST